MAP2K1 and colorectal carcinoma: Activation of WNT/β-catenin signaling, occurring in most CRC tumors, has been identified as a resistance mechanism to PI3K/mTOR treatment in CRC cell lines76; some data suggest that this resistance can be overcome by the addition of a MEK1/2 inhibitor, such as pimasertib77.